AbbVie Strikes Hepatitis C Discount Deal With AIDS Drug Programs - (Bloomberg via NewsPoints Desk)

  • AbbVie agreed to provide its $1000-a-day hepatitis C treatment, Viekira Pak, to state-based HIV drug programmes at a substantial discount, Bloomberg reported Friday.
  • Britten Pund, associate director of healthcare access for the National Alliance of State & Territorial AIDS Directors, would not give the exact price, but said the offer was below the wholesale acquisition cost and less than a mandated 23-percent discount for drugs under a programme for poor and under-served patient programmes.
  • The ADAP Crisis Task Force had "previously tried to negotiate with Gilead on the price of Sovaldi, and Gilead had declined to negotiate," said Pund.
  • She added that "we did not have a specific conversation about Harvoni, but we hope to reignite those conversations."

To read more NewsPoints articles, click here.